Clinical Trial Detail

NCT ID NCT01191697
Title CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute

esophageal carcinoma

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma


Bevacizumab + Trastuzumab

Capecitabine + Oxaliplatin

Age Groups: adult

Additional content available in CKB BOOST